premieranalysis

premieranalysis

NIO - completed wave 2 , and it is time for wave 3 (TP1 = 46,27 , tp 2= 58,5 )

premieranalysis

LMND - long

premieranalysis

PLTR - TARGET 55 USD in maxim 4 months

premieranalysis Updated 

Black Diamond Therapeutics, Inc. (BDTX) wait for withdrawal up to 27 usd and then strong buy for 12 months

premieranalysis

Not a financial advice. Do your own research and have a happy trading. 70% of US electricity production is consumed by buildings. ESG/regulatory goals require these buildings to become net zero energy buildings over the next decade. This drives a huge total addressable market of ~$1T for Smart Windows. View Inc. is the leader in this space with a market share of...

premieranalysis

Not a financial advice. Do your own research and have a happy trading. possible buy opportunity at CRISPR, the pullback seems to be over, the company - the big leader among gene-editing pioneers - is extraordinary, the current capitalization of 12, B poae rises in the next max 5 years to 100B. Green resistance is the maximum reached by the company since it is listed.

premieranalysis

Not a financial advice. Do your own research and have a happy trading. - the price is in decline both on h4 and daily - on H1 it starts to climb, a channel has formed that coincides with a support

premieranalysis Updated 

Inpixon (INPX) The company is indebted to the limit of the maximum tolerable (debt / asset = 71.62%). The results from 2019 and 2020 show a financial recovery for the company - increasing revenues, from 3.8 million USD (2018), 6.3 million (2019) and 7.3 million TTM 2020 - increase in gross margin: from 2.7 million in 2018 to 5.4 million TTM 2020 I recommend...

premieranalysis

For the next few days, the price will make an accumulation channel between 2.05 and 2.50. If it breaks the lower limit of the channel, then it will go to the monthly support of 1.83. For short term transactions you can enter buy (only buy, not sell !!) at the lower limit of the channel. If it breaks the lower limit of the channel, then it will go to the monthly...

premieranalysis Updated 

POLA launched the rocket - target 22.75

premieranalysis

the price will pull back to 1.90 then 1.50 (50% fibo retracement), the trend is upward, it does not change! watch the withdrawal and then you can buy

premieranalysis

a perfect and strong buy for the price 7,30 and 10 usd! Good luck!

premieranalysis

The company is working in the robotics field. In its product pipeline are several unique and advantageous breakthroughs. This includes the Enos System, which offers 2D/3D vision systems and multi-articulating surgical instruments in one ergonomically designed work station. Titan is also working on licensing its products to outside companies wishing to utilize its...

premieranalysis

Pay attention to the day of February 10 when the estimated results for 2020 are announced. If they are positive, then the price will rise to 8.90 and then the next monthly resistance from 10usd Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company...

premieranalysis Updated 

Preliminary unaudited fourth quarter 2020 total revenue is expected to be $7.8 million, including product revenue of $5.8 million, representing growth of 155% and 274% respectively, compared to the prior year period Preliminary unaudited full year 2020 total revenue is expected to be $18.1 million, including product revenue of $11.7 million, representing growth...

premieranalysis Updated 

the price had 3 attempts to break the support from 10.05 and failed. If the price toch 12.00 , then it's time to buy . The company lost nearly 30 million on sales of $4.5 million in the first nine months of 2020. If it manages to break the support, then we consider the price from 9 and the next 7.50 .

premieranalysis Updated 

SUNWORKS - buy now to 25.6

premieranalysis Updated 

Athersys, Inc. The solid gain came after the company and the University of Texas Health Science Center at Houston announced the enrollment of the first patient in a phase 2 clinical study evaluating the company's MultiStem cell therapy as a potential early treatment for traumatic injuries. The company doesn't have any approved products on the market ye t, so...